Related Experiment Videos
Gout in 2006: the perfect storm.
1VAMC/UCSD, 3350La Jolla Village Drive, 111K, San Diego, California 92161, USA.
Bulletin of the NYU Hospital for Joint Diseases
|November 24, 2006
Summary
Recent advances enhance gout understanding and treatment. Novel therapies target hyperuricemia and inflammation, addressing limitations of current gout medications.
Area of Science:
- Rheumatology
- Nephrology
- Immunology
Background:
- Gout is a complex inflammatory arthritis characterized by hyperuricemia.
- Current therapies for gout have limitations in efficacy and safety.
- The clinical presentation and understanding of gout are evolving.
Purpose of the Study:
- To review recent mechanistic and therapeutic advances in gout.
- To discuss novel therapeutic targets for hyperuricemia and gouty inflammation.
- To highlight the limitations of existing gout treatments.
Main Methods:
- Literature review of recent studies on gout pathophysiology and treatment.
- Analysis of the role of URAT1 in renal urate reabsorption.
- Evaluation of novel therapeutic agents including xanthine oxidase inhibitors and uricase.
- Summary of innate immune response mechanisms in gouty inflammation.
Main Results:
- URAT1 plays a key role in renal urate reabsorption contributing to hyperuricemia.
- Novel xanthine oxidase inhibitors and recombinant uricase show promise for managing hyperuricemia.
- Targeting caspase-1 and IL-1beta offers new strategies for gouty inflammation.
Conclusions:
- Advances in understanding gout pathophysiology are driving the development of novel therapeutics.
- New treatments aim to overcome the limitations of allopurinol and uricosurics.
- Targeting innate immune pathways presents a promising avenue for managing gout flares.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:25Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is the backward flow of stomach contents (acid, pepsin, or bile) into the esophagus, causing mucosal inflammation known as esophagitis. It results from failure of antireflux mechanisms, mainly the lower esophageal sphincter (LES), influenced by mechanical and physiological factors.Etiology and Risk FactorsGERD develops when LES function is weakened or when intra-abdominal pressure increases. Risk factors include aging, obesity, and sliding hiatal hernia,...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...